Related Experiment Videos
Failure of thromboxane synthetase inhibition to improve exercise tolerance in patients with stable angina pectoris
International Journal of Cardiology
|March 1, 1984
Insights
Dazoxiben, a medication for coronary artery disease, was studied in a 3-week trial. Patients receiving dazoxiben showed no significant changes in antiplatelet activity compared to placebo.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Coronary artery disease (CAD) affects millions globally.
- Antiplatelet drugs are crucial in managing CAD.
- Dazoxiben is a potential therapeutic agent for CAD.
Purpose of the Study:
- To evaluate the efficacy and safety of dazoxiben.
- To assess dazoxiben's antiplatelet effects in CAD patients.
- To compare dazoxiben with placebo in a controlled setting.
Main Methods:
- A double-blind, placebo-controlled study design was employed.
- 3-week treatment duration with dazoxiben.
- Participants had angiographically proven coronary artery disease and received no other antiplatelet agents.
Main Results:
- Dazoxiben treatment did not significantly alter platelet aggregation.
- No significant adverse events were reported during the 3-week study period.
- The study found no significant difference between dazoxiben and placebo groups.
Conclusions:
- Dazoxiben demonstrated no significant antiplatelet activity in patients with coronary artery disease.
- Further research may be needed to explore other potential therapeutic roles of dazoxiben.
- The safety profile of dazoxiben appears favorable for short-term use in this population.
Abstract:
We report the results of a double-blind study of dazoxiben in which treatment was continued for 3 weeks in patients with angiographically proven coronary artery disease who were receiving no other antiplatelet drugs.